# A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver

> **NCT00582400** · PHASE2 · TERMINATED · sponsor: **The University of Texas Medical Branch, Galveston** · enrollment: 9 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** arsenic trioxide

## Key facts

- **NCT ID:** NCT00582400
- **Lead sponsor:** The University of Texas Medical Branch, Galveston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
- **Last updated:** 2016-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00582400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00582400, "A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00582400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*